ClinicalTrials.gg
CompletedNCT04395261Updated Sep 15, 2023

Wideband Tympanometry in Otitis Media With Effusion

An observational study in Otitis Media With Effusion, sponsored by Pamukkale University. Completed. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by Pamukkale University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
202
Sex
All
01

Study summary

The investigators asked the question if they can better estimate the middle ear status in OME that help them to decide between early intervention or longer follow up.

Read the detailed description

Purpose: Otitis media with effusion is an important problem in childhood. After proper diagnosis, generally 3 months of follow up has been recommended before surgical tympanostomy tube insertion. If the physician can estimate the status of the middle ear or fluid type better with a non-invasive method, we can suggest an early operation to these patients or decide to follow up more with no intervention. The purpose of the study is to compare the surgically confirmed middle ear effusions with wideband absorbance values and to differentiate them noninvasively before the operation.

Methods: A total of 123 children that were followed 3 months and treated surgically with the diagnosis of OME were included. Eighty-two sex, age-matched children were tested as control with wideband tympanometry. Ears were divided into four groups according to findings in the operation: serous, mucoid, adhesive, empty. Resonance frequency, 226 Hz, 1000 Hz compliance, Wideband Peak pressure, Absorbance measurements used for comparison.

02

Conditions studied

  • Otitis Media With Effusion
03

In context

Otitis Media with Effusion

85 studies on the registry are indexed under Otitis Media with Effusion; 15 are open to participants now.

This study's enrollment of 202 is above the median of 125 across 20 observational studies indexed under Otitis Media with Effusion.

Browse Otitis Media with Effusion studies →

Lead sponsor

Pamukkale University is the lead sponsor of 340 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

children with otitis media with effusion

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients were diagnosed by ear examination, pneumatic otoscopy, and type B tympanogram with 226 Hz tympanometry. They were followed for 3 months with proper medication. After 3 months if there was no change with ear examination and 226 Hz tympanometry, surgical ventilation tube insertion was offered.

Exclusion criteria

Exclusion Criteria:

  • The patients with chronic ear diseases, ototoxic drug use, neurologic disease were excluded.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
202 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 0

    Patients were divided into groups according to observation in surgery Empty ear in operation

    Diagnostic Test: Wideband Tympanometry

  • Group 1

    Patients were divided into groups according to observation in surgery Serous fluid in operation

    Diagnostic Test: Wideband Tympanometry

  • Group 2

    Patients were divided into groups according to observation in surgery Mucoid fluid in operation

    Diagnostic Test: Wideband Tympanometry

  • Group 3

    Patients were divided into groups according to observation in surgery Adhesive tympanic membrane in operation

    Diagnostic Test: Wideband Tympanometry

  • Group 4

    Control group. Subjects with no otitis media with effusion

    Diagnostic Test: Wideband Tympanometry

Interventions

  • Diagnostic testWideband Tympanometry
06

What researchers measure

Primary outcomes

  1. Resonance frequency

    Wideband resonance frequency was measured

    Time frame: The same 1 day with the operation

  2. Absorbance

    Wideband absorbance of frequencies between 250-8000 Hz were measured

    Time frame: The same 1 day with the operation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Data will be available in the university depository

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Dec 2018, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2020
First posted
May 20, 2020
StartActual
Jan 1, 2016
Primary completionActual
Dec 30, 2018
CompletionActual
Dec 30, 2018
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04395261
Responsible party
Fazıl Necdet Ardıç (Prof.Dr., Pamukkale University) — Principal investigator
First posted
May 20, 2020
Start date
Jan 1, 2016
Primary completion
Dec 30, 2018
Completion
Dec 30, 2018
Last update
Sep 15, 2023

Study contacts

Fazıl N Ardıç, MD
principal investigator · Chief of Department

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion